BCYC
Bicycle Therapeutics plc
BCYC lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
BCYC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BCYC's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
BCYC PE Valuation
BCYC has no meaningful PE right now: it lost money over the past year.
BCYC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect BCYC's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
BCYC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.03 | +$1.61 |
| Q2 2026 | -$2.73 | +$0.80 |
| Q1 2026 | -$3.15 | +$0.01 |
| Q4 2025 | -$3.16 | -$0.26 |
| Q3 2025 | -$3.64 | -$0.40 |
| Q2 2025 | -$3.53 | +$0.23 |
| Q1 2025 | -$3.16 | +$1.24 |
| Q4 2024 | -$2.90 | +$2.18 |
BCYC is still losing money, but far less than before: $2.03 per share over the past year, against $5.08 at its worst in late 2023.
BCYC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $34.1M | +190% |
| Q2 2026 | $629K | -78% |
| Q1 2026 | $887K | -91% |
| Q4 2025 | $48M | +1193% |
| Q3 2025 | $11.7M | +338% |
| Q2 2025 | $2.9M | -69% |
| Q1 2025 | $10M | -49% |
| Q4 2024 | $3.7M | -30% |
BCYC's revenue is growing: $34M last quarter, up 190% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -40% | +519 points |
| Q2 2026 | -8674% | -5708 points |
| Q1 2026 | -7382% | -6679 points |
| Q4 2025 | -52% | +1773 points |
| Q3 2025 | -559% | +1827 points |
| Q2 2025 | -2966% | -2468 points |
| Q1 2025 | -704% | -541 points |
| Q4 2024 | -1825% | -807 points |
BCYC's operating margin was −40% last quarter, up 519 points from the same quarter a year ago, near the top of its range since 2019.
BCYC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40.6M | +$31.2M |
| Q2 2026 | -$49.9M | +$23.4M |
| Q1 2026 | -$66.6M | +$20.3M |
| Q4 2025 | -$19.9M | -$10.2M |
| Q3 2025 | -$71.8M | -$31.6M |
| Q2 2025 | -$73.3M | -$28.2M |
| Q1 2025 | -$87M | -$16.1M |
| Q4 2024 | -$9.8M | +$37.6M |
BCYC has burned cash in almost every quarter: −$177M over the past year, against −$242M the year before.
BCYC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +175K shares |
| 1 year | +1% | +676K shares |
| 3 years | +77% | +30.4M shares |
| 5 years | +179% | +44.9M shares |
| Available history | +290% | +52.1M shares |
BCYC has 70M diluted shares, up 1% from a year ago.
BCYC Net Leverage
BCYC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BCYC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 20.6 | Neutral |
BCYC's weekly RSI is 39 (neutral) and its Stochastic is 21 (neutral).
BCYC PE vs Healthcare Sector
BCYC has no meaningful PE right now: it lost money over the past year.
BCYC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.59 | 3.9% below |
| 20 week MA | $3.89 | 11% below |
| 50 week MA | $4.79 | 28% below |
| 100 week MA | $6.92 | 50% below |
| 200 week MA | $14.4 | 76% below |
BCYC is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
BCYC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.07 | $19.9 | +119% |
| 2021 | $19.9 | $60.3 | +203% |
| 2022 | $60.3 | $30.0 | -50% |
| 2023 | $30.0 | $18.1 | -40% |
| 2024 | $18.1 | $14.6 | -20% |
| 2025 | $14.6 | $6.82 | -53% |
| 2026 YTD | $6.82 | $3.45 | -49% |
BCYC has finished four years in a row lower, and it's down 49% so far in 2026.